Avdoralimab

Generic Name: Avdoralimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2226393-85-5

Unique Ingredient Identifier: DW4CE8MKS9

Background: Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

Phase 2

Completed

Conditions: SARS-CoV-2 (COVID-19) Infection
Advanced or Metastatic Hematological or Solid Tumor

Interventions: Other: Standard of care
Drug: Autophagy inhibitor (GNS651)
Drug: Avdoralimab
Drug: Monalizumab

First Posted Date: 2020-04-03

Last Posted Date: 2022-09-30

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 19

Registration Number: NCT04333914

Locations: 🇫🇷
AP-HP Hôpital Bichat Claude Bernard, Paris, France
🇫🇷
GH Diaconesses Croix Saint Simon, Paris, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 9 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy